US경제·CNBC Business RSS· 번역 중
AI가 열심히 번역 중이에요 🤖
곧 한글 번역본을 제공해드릴게요. 잠시만 기다려주세요!
The divide between Eli Lilly and Novo Nordisk is widening after their latest earnings
The divide between Eli Lilly and Novo Nordisk is widening after their latest earnings
2026.08.07 01:28
AI 감성 분석
롱 (매수 신호)롱 62%숏 38%
시장 선도 기업인 일라이 릴리의 모멘텀이 강화되는 반면, 노보 노디스크에 대한 압박이 발생하여 긍정적인 방향으로 해석됩니다.
핵심 요약
As Lilly widens its lead in the obesity race, Novo is still racing to win back market share and restore investor confidence in its pipeline.
As Lilly widens its lead in the obesity race, Novo is still racing to win back market share and restore investor confidence in its pipeline.
Original Article
The divide between Eli Lilly and Novo Nordisk is widening after their latest earnings
As Lilly widens its lead in the obesity race, Novo is still racing to win back market share and restore investor confidence in its pipeline.
Source: https://www.cnbc.com/2026/08/06/eli-lilly-novo-nordisk-earnings-glp1-market.html